Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Myeloid, Acute 3Rhabdomyosarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Leukemia, Biphenotypic, Acute 2Sarcoma, Myeloid 1Sarcoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1PRETEXT I Hepatoblastoma 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Malignant mesenchymal tumor 1Ganglioneuroblastoma 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

Doxorubicin 14pembrolizumab 11Specimen Handling 11Magnetic Resonance Spectroscopy 10Biopsy 9Cyclophosphamide 8X-Rays 7Radiotherapy 7Nivolumab 7Ifosfamide 7Phantoms, Imaging 6Gemcitabine 6liposomal doxorubicin 5Temozolomide 5Radiation 5tazemetostat 4palbociclib 4Trabectedin 4Nuclear Medicine Department, Hospital 4Irinotecan 4Ipilimumab 4pazopanib 3larotrectinib 3fludarabine 3cabozantinib 3atezolizumab 3Surveys and Questionnaires 3Radiation Dose Hypofractionation 3Proton Therapy 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Dexrazoxane × 90 days × Clear all
NCT00077285 2026-05-22

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
65 enrolled
Sarcoma

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡